156 related articles for article (PubMed ID: 32291726)
1. Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis.
Bazarbashi S; De Vol EB; Maraiki F; Al-Jedai A; Ali AA; Alhammad AM; Aljuffali IA; Iskedjian M
Pharmacoecon Open; 2020 Dec; 4(4):625-633. PubMed ID: 32291726
[TBL] [Abstract][Full Text] [Related]
2. Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity.
Mavrodi A; Aletras V; Spanou A; Niakas D
Pharmacoecon Open; 2017 Dec; 1(4):291-300. PubMed ID: 29441505
[TBL] [Abstract][Full Text] [Related]
3. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
Mavrodi A; Aletras V
Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
[TBL] [Abstract][Full Text] [Related]
4. Estimating a WTP-based value of a QALY: the 'chained' approach.
Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
Nimdet K; Ngorsuraches S
BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
[TBL] [Abstract][Full Text] [Related]
6. Willingness to pay for a quality-adjusted life-year: the individual perspective.
Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
[TBL] [Abstract][Full Text] [Related]
7. Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP).
Moradi N; Rashidian A; Rasekh HR; Olyaeemanesh A; Foroughi M; Mohammadi T
Iran J Pharm Res; 2017; 16(2):823-833. PubMed ID: 28979338
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.
Huang L; Peng X; Sun L; Zhang D
Cost Eff Resour Alloc; 2023 Jun; 21(1):37. PubMed ID: 37277820
[TBL] [Abstract][Full Text] [Related]
10. Willingness to pay for one quality-adjusted life year in Iran.
Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
Cost Eff Resour Alloc; 2019; 17():4. PubMed ID: 30867654
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
Song HJ; Lee EK
Medicine (Baltimore); 2018 Sep; 97(38):e12453. PubMed ID: 30235732
[TBL] [Abstract][Full Text] [Related]
12. The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method.
Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
Pharmacoecon Open; 2019 Sep; 3(3):311-319. PubMed ID: 30617954
[TBL] [Abstract][Full Text] [Related]
13. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
Thavorncharoensap M; Teerawattananon Y; Natanant S; Kulpeng W; Yothasamut J; Werayingyong P
Clinicoecon Outcomes Res; 2013; 5():29-36. PubMed ID: 23345984
[TBL] [Abstract][Full Text] [Related]
14. Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.
Nielsen JS; Gyrd-Hansen D; Kjaer T
Health Econ; 2021 May; 30(5):923-931. PubMed ID: 33569834
[TBL] [Abstract][Full Text] [Related]
15. Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.
Shafie AA; Lim YW; Chua GN; Hassali MA
Clinicoecon Outcomes Res; 2014; 6():473-81. PubMed ID: 25364267
[TBL] [Abstract][Full Text] [Related]
16. The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.
Ryen L; Svensson M
Health Econ; 2015 Oct; 24(10):1289-1301. PubMed ID: 25070495
[TBL] [Abstract][Full Text] [Related]
17. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
Moradi N; Woldemichael A; Malekian P; Rotvandi DM; Rezaei S
Cost Eff Resour Alloc; 2020; 18():47. PubMed ID: 33110399
[TBL] [Abstract][Full Text] [Related]
18. Monetary value of health-a practical decision-making framework combining equity considerations and WTP.
Ribarić E; Velić I; Bobinac A
Eur J Health Econ; 2024 May; ():. PubMed ID: 38769211
[TBL] [Abstract][Full Text] [Related]
19. Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
Ye Z; Abduhilil R; Huang J; Sun L
Appl Health Econ Health Policy; 2022 Nov; 20(6):893-904. PubMed ID: 35934772
[TBL] [Abstract][Full Text] [Related]
20. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
Olofsson S; Norrlid H; Persson U
J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
